Potential Applications of Pharmacogenomics to Heart Failure Therapies

Heart Failure Clinics

Volumn 10, Issue 4, 2014, Pages 599-606

  Parikh, Kishan S ^a   Ahmad, Tariq ^a,b   Fiuzat, Mona ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Heart failure; Personalized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

DNA POLYMORPHISM; DRUG DOSE REGIMEN; GENETIC VARIABILITY; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATIENT SELECTION; PHARMACOGENOMICS; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUDDEN CARDIAC DEATH; TREATMENT RESPONSE; COMPLICATION; DEATH, SUDDEN, CARDIAC; GENETICS; PHARMACOGENETICS;

DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; PHARMACOGENETICS;

EID: 84908053565     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.07.007     Document Type: Review

References (52)

1. Osler W. Osler: oesophagismus. Principles and practice of medicine 1892, Appleton & Co, New York.
2. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644-1648.
3. Garrod A.E. Inborn errors of metabolism 1923, Oxford Univ Press, London. 2nd Edition.
4. Charlab R., Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol 2013, 1015:3-22.
5. Cappola T.P., Dorn G.W. Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet 2011, 4:701-709.
6. Talameh J.A., Lanfear D.E. Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep 2012, 9:23-32.
7. Ahmad T., O'Connor C.M. Therapeutic implications of biomarkers in chronic heart failure. Clin Pharmacol Ther 2013, 94:468-479.
8. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008, 117:2544-2565.
9. Fiuzat M., O'Connor C.M., Gueyffier F., et al. Biomarker-guided therapies in heart failure: a forum for unified strategies. JCard Fail 2013, 19:592-599.
10. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344:1651-1658.
11. Packer M., Bristow M., Cohn J., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. NEngl J Med 1996, 334:1349.
12. Group M.H. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001.
13. Drummond G.A., Squire I.B. The cardiac insufficiency bisoprolol study II. Lancet 1999, 353(9161):1361.
14. Flather M.D., Shibata M.C., Coats A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
15. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. Apolymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103:11288-11293.
16. Fiuzat M., Neely M.L., Starr A.Z., et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail 2013, 15:258-266.
17. Perez J.M., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003, 9:1300-1305.
18. Domanski M.J., Krause-Steinrauf H., Massie B.M., et al. Acomparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. JCard Fail 2003, 9:354-363.
19. Walsh R., Farmer R., Kelly M., et al. Human myocardial b1389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. JCard Fail 2008, 14:S8.
20. Bristow M.R., Krause-Steinrauf H., Nuzzo R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004, 110:1437-1442.
21. White H.L., de Boer R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003, 5:463-468.
22. Small K.M., Wagoner L.E., Levin A.M., et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. NEngl J Med 2002, 347:1135-1142.
23. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. JAm Coll Cardiol 2004, 44:2019-2026.
24. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT trial. JAm Coll Cardiol 2006, 48:1277-1282.
25. Brand E., Chatelain N., Mulatero P., et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998, 32:198-204.
26. White P.C., Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995, 21:437-442.
27. Darbar D. Genomics, heart failure and sudden cardiac death. Heart Fail Rev 2010, 15:229-238.
28. Sanders G.D., Kong M.H., Al-Khatib S.M., et al. Cost-effectiveness of implantable cardioverter defibrillators in patients>or=65 years of age. Am Heart J 2010, 160:122-131.
29. Huikuri H.V., Castellanos A., Myerburg R.J. Sudden death due to cardiac arrhythmias. NEngl J Med 2001, 345:1473-1482.
30. Tung R., Zimetbaum P., Josephson M.E. Critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. JAm Coll Cardiol 2008, 52:1111-1121.
31. Zipes D.P., Wellens H.J. Sudden cardiac death. Circulation 1998, 98:2334-2351.
32. Noseworthy P.A., Newton-Cheh C. Genetic determinants of sudden cardiac death. Circulation 2008, 118:1854-1863.
33. Moss A.J., Zareba W., Hall W.J., et al. Effectiveness and limitations of β-Blocker therapy in congenital long-QT syndrome. Circulation 2000, 101(6):616-623.
34. Frangiskakis J.M., London B. Targeting device therapy: genomics of sudden death. Heart Fail Clin 2010, 6:93-100.
35. Friedlander Y., Siscovick D.S., Weinmann S., et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998, 97:155-160.
36. Jouven X., Desnos M., Guerot C., et al. Predicting sudden death in the population: the Paris prospective study I. Circulation 1999, 99:1978-1983.
37. Kaikkonen K.S., Kortelainen M.L., Linna E., et al. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006, 114:1462-1467.
38. Dekker L.R.C., Bezzina C.R., Henriques J.P.S., et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006, 114:1140-1145.
39. Benza R.L., Miller D.P., Gomberg-Maitland M., et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010, 122:164-172.
40. Ma L., Roman-Campos D., Austin E.D., et al. Anovel channelopathy in pulmonary arterial hypertension. NEngl J Med 2013, 369:351-361.
41. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
42. Duarte J.D., Hanson R.L., Machado R.F. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol 2013, 9:335-349.
43. Soubrier F., Chung W.K., Machado R., et al. Genetics and genomics of pulmonary arterial hypertension. JAm Coll Cardiol 2013, 62:D13-D21.
44. Koehler R., Grünig E., Pauciulo M.W., et al. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. JMed Genet 2004, 41:e127.
45. Larkin E.K., Newman J.H., Austin E.D., et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:892-896.
46. Harper A.R., Topol E.J. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012, 30:1117-1124.
47. Goldspiel B.R., Flegel W.A., Dipatrizio G., et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. JAm Med Inform Assoc 2013, 21(3):522-528. 10.1136/amiajnl-2013-001873.
48. Roden D.M., Wilke R.A., Kroemer H.K., et al. Pharmacogenomics: the genetics of variable drug responses. Circulation 2011, 123:1661-1670.
49. Relling M.V., Klein T.E. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011, 89:464-467.
50. Dewey F.E., Grove M.E., Pan C., et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014, 311:1017-1019.
51. Bristow M.R. Pharmacogenetic targeting of drugs for heart failure. Pharmacol Ther 2012, 134:107-115.
52. Ahmad T., Voora D., Becker R.C. The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nat Rev Cardiol 2011, 8:560-571.